Works by Borad, Mitesh
Results: 81
Proteolysis targeting chimera (PROTAC)-driven antibody internalization of oncogenic cell surface receptors.
- Published in:
- Communications Biology, 2024, v. 7, n. 1, p. 1, doi. 10.1038/s42003-024-07439-0
- By:
- Publication type:
- Article
Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination.
- Published in:
- NPJ Vaccines, 2022, v. 7, n. 1, p. 1, doi. 10.1038/s41541-022-00569-8
- By:
- Publication type:
- Article
Decline in the seroprevalence of syphilis markers among first-time blood donors in Libreville (Gabon) between 2004 and 2016.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A Multicenter, Open-Label, Phase 1 Study Evaluating the Safety and Tolerability of Pegaspargase in Combination with Gemcitabine in Advanced Metastatic Solid Tumors and Lymphoma.
- Published in:
- Cancer Investigation, 2015, v. 33, n. 5, p. 172, doi. 10.3109/07357907.2015.1019677
- By:
- Publication type:
- Article
Oncolytic Adenoviruses in Gastrointestinal Cancers.
- Published in:
- Biomedicines, 2018, v. 6, n. 1, p. 33, doi. 10.3390/biomedicines6010033
- By:
- Publication type:
- Article
<sup>18</sup>F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.
- Published in:
- British Journal of Cancer, 2018, v. 118, n. 2, p. 153, doi. 10.1038/bjc.2017.327
- By:
- Publication type:
- Article
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.
- Published in:
- 2018
- By:
- Publication type:
- corrected article
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.
- Published in:
- 2017
- By:
- Publication type:
- journal article
MetaMarker: a pipeline for de novo discovery of novel metagenomic biomarkers.
- Published in:
- Bioinformatics, 2019, v. 35, n. 19, p. 3812, doi. 10.1093/bioinformatics/btz123
- By:
- Publication type:
- Article
Using Naïve Bayesian Analysis to Determine Imaging Characteristics of KRAS Mutations in Metastatic Colon Cancer.
- Published in:
- Diagnostics (2075-4418), 2017, v. 7, n. 3, p. 50, doi. 10.3390/diagnostics7030050
- By:
- Publication type:
- Article
Circulating Tumor DNA Testing for Minimal Residual Disease and Its Application in Colorectal Cancer.
- Published in:
- Cells (2073-4409), 2025, v. 14, n. 3, p. 161, doi. 10.3390/cells14030161
- By:
- Publication type:
- Article
Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date.
- Published in:
- Cancer Management & Research, 2023, v. 15, p. 1025, doi. 10.2147/CMAR.S326060
- By:
- Publication type:
- Article
Introducing the PLOS collection on rare cancer.
- Published in:
- PLoS ONE, 2024, v. 19, n. 7, p. 1, doi. 10.1371/journal.pone.0308087
- By:
- Publication type:
- Article
An overview of up-and-coming immune checkpoint inhibitors for pancreatic cancer.
- Published in:
- Expert Opinion on Pharmacotherapy, 2024, v. 25, n. 1, p. 79, doi. 10.1080/14656566.2024.2304125
- By:
- Publication type:
- Article
Repurposing live attenuated trivalent MMR vaccine as costeffective cancer immunotherapy.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.1042250
- By:
- Publication type:
- Article
A Phase I Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Topotecan at 4 mg/m² Administered Weekly as a 30-Minute Intravenous Infusion in Patients With Cancer.
- Published in:
- Journal of Clinical Pharmacology, 2010, v. 50, n. 3, p. 268, doi. 10.1177/0091270009343699
- By:
- Publication type:
- Article
Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma.
- Published in:
- PLoS Genetics, 2014, v. 10, n. 2, p. 1, doi. 10.1371/journal.pgen.1004135
- By:
- Publication type:
- Article
Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma.
- Published in:
- International Journal of Clinical Oncology, 2013, v. 18, n. 5, p. 934, doi. 10.1007/s10147-012-0475-8
- By:
- Publication type:
- Article
APRI score is not predictive of post-surgical outcomes in cholangiocarcinoma patients.
- Published in:
- Annals of Gastroenterology, 2024, v. 37, n. 1, p. 95, doi. 10.20524/aog.2024.0845
- By:
- Publication type:
- Article
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-36399-y
- By:
- Publication type:
- Article
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-36399-y
- By:
- Publication type:
- Article
Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection.
- Published in:
- Genome Biology, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s13059-021-02449-1
- By:
- Publication type:
- Article
Serial Circulating Free DNA Testing Can Detect New Genetic Alterations in Patients Undergoing Treatment for Pancreas Cancer... [including commentary by Daniel G. Haller].
- Published in:
- Oncology (08909091), 2020, v. 34, n. 11, p. 476
- By:
- Publication type:
- Article
PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2024, v. 13, n. 3, p. 256, doi. 10.1159/000533650
- By:
- Publication type:
- Article
Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response.
- Published in:
- Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-49286-x
- By:
- Publication type:
- Article
Pharmacotherapeutic options for pancreatic ductal adenocarcinoma.
- Published in:
- Expert Opinion on Pharmacotherapy, 2022, v. 23, n. 18, p. 2079, doi. 10.1080/14656566.2022.2149322
- By:
- Publication type:
- Article
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 1, p. 127, doi. 10.1007/s10637-024-01420-8
- By:
- Publication type:
- Article
A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 134, doi. 10.1007/s10637-021-01170-x
- By:
- Publication type:
- Article
A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 81, doi. 10.1007/s10637-021-01164-9
- By:
- Publication type:
- Article
Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance).
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 4, p. 1072, doi. 10.1007/s10637-021-01090-w
- By:
- Publication type:
- Article
A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 684, doi. 10.1007/s10637-018-0703-9
- By:
- Publication type:
- Article
E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 636, doi. 10.1007/s10637-018-0668-8
- By:
- Publication type:
- Article
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 2, p. 180, doi. 10.1007/s10637-016-0407-y
- By:
- Publication type:
- Article
Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 1, p. 96, doi. 10.1007/s10637-015-0308-5
- By:
- Publication type:
- Article
Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 710, doi. 10.1007/s10637-014-0096-3
- By:
- Publication type:
- Article
Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 4, p. 1056, doi. 10.1007/s10637-012-9909-4
- By:
- Publication type:
- Article
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 6, p. 2334, doi. 10.1007/s10637-011-9774-6
- By:
- Publication type:
- Article
Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 5, p. 931, doi. 10.1007/s00280-014-2424-x
- By:
- Publication type:
- Article
Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups.
- Published in:
- NPJ Precision Oncology, 2021, v. 5, n. 1, p. 1, doi. 10.1038/s41698-021-00164-5
- By:
- Publication type:
- Article
Emerging role of precision medicine in biliary tract cancers.
- Published in:
- NPJ Precision Oncology, 2018, v. 2, n. 1, p. N.PAG, doi. 10.1038/s41698-018-0064-z
- By:
- Publication type:
- Article
Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study.
- Published in:
- Oncologist, 2024, v. 29, n. 11, p. 986, doi. 10.1093/oncolo/oyae142
- By:
- Publication type:
- Article
Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
- Published in:
- Oncologist, 2023, v. 28, n. 11, p. 928, doi. 10.1093/oncolo/oyad149
- By:
- Publication type:
- Article
Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma.
- Published in:
- Oncologist, 2023, v. 28, n. 10, p. 917, doi. 10.1093/oncolo/oyad144
- By:
- Publication type:
- Article
Role of Systemic Therapy in Resectable Colorectal Liver Metastases: Systematic Review and Network Meta-Analysis.
- Published in:
- Oncologist, 2022, v. 27, n. 12, p. 1034, doi. 10.1093/oncolo/oyac212
- By:
- Publication type:
- Article